Cystic Fibrosis Ireland avatar
Cystic Fibrosis Ireland

CFI is a voluntary organisation that was set up by parents in 1963 to improve the treatment and facilities for people with Cystic Fibrosis.

Health - Ireland
  • Transparency score on:

    Projects 6.0

    Results 0.0

    Financials 2.3

    Transparency

2.8 / 10

2025 PLAN

€6,060

raised of €10,000 goal

2

altruist

Create fundraising page

2025 PLAN

€6,060

raised of €10,000 goal

2

altruist

Create fundraising page

Donations made here are eligible for a charity to reclaim in tax paid in Ireland

Cause

Cystic fibrosis (CF) is an inherited chronic disease that primarily affects the lungs and digestive system of about 1200 children and adults in the Ireland (70,000 worldwide). A defective gene and its protein product cause the body to produce unusually thick, sticky mucus that clogs the lungs and leads to life-threatening lung infections and obstructs the pancreas and stops natural enzymes from helping the body break down and absorb food. 

Statistics:

  • About 50 new cases of cystic fibrosis in Ireland are diagnosed each year.
  • Because of new born screening, most babies with CF should now be diagnosed quickly.
  • Around 55% of the CF patient population in Ireland is aged 18 or older.
  • The predicted median age of survival for a person with CF is in the early and mid-30’s in Ireland.


    • Response

    Our mission is to assist the development of the means to cure and control Cystic Fibrosis (CF), to promote the interests and welfare of persons with Cystic Fibrosis in Ireland and to assume advocacy for them and their needs resultant from their having Cystic Fibrosis (CF).

    Projects

    1. CFI working with our branches and the generous support from the general public has provided €7.5m to improve CF centres throughout Ireland in 2014 and 2015>

    2. CFI continue to play and important role in ensuring access to new and innovative treatments for CF. Kalydeco (the first drug that treated the underlying cause of CF) was made available in 2013, suitable for around 11% of the CF population in Ireland. CFI are currently seeking additional access to this drug for 2-5 years and access to Orkambi, another new drug treating the underlying cause of CF, which could benefit another 50% of the CF population in Ireland.

    3. CFI are seeking the continued improvement in the rate of double lung transplants. The rate of transplants increased from 4 in 2012 to 19 in 2014 in Ireland. CFI is also supporting the Mater Hospital in terms of the resources required for Post -Transplant care